Compositions for treating inflammation and uses thereof
Provided herein are, inter alia, microbial compositions and methods of using the same. The microbial compositions provided include, inter alia, therapeutically effective amounts of Lactobacillus johnsonii, Faecalibacterium prausnitzii, Akkermansia muciniphila, Myxococcus xanthus and Pediococcus pentosaceus and are particularly useful for methods of treating and preventing inflammatory diseases.
1. A pharmaceutical composition, comprising:
a purified bacterial population comprising a strain of Lactobacillus sp., Faecalibacterium sp., and Akkermansia sp.,
wherein the purified bacterial population is present in an effective amount for reducing the incidence of allergic inflammation in a subject in need thereof, and wherein the pharmaceutical composition is in the form of a suspension.
2. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is formulated to be suitable for gut colonization in the subject.
3. The pharmaceutical composition of claim 1 , wherein the Lactobacillus sp. is Lactobacillus johnsonii or Lactobacillus crispatus.
4. The pharmaceutical composition of claim 1 , wherein the Faecalibacterium sp. is Faecalibacterium prausnitzii.
5. The pharmaceutical composition of claim 1 , wherein the Akkermansia sp. is Akkermansia muciniphila.
6. The pharmaceutical composition of claim 1 , wherein the Lactobacillus sp. is Lactobacillus zeae, Lactobacillus acidipiscis, Lactobacillus acidophilus, Lactobacillus agilis, Lactobacillus aviarius, Lactobacillus brevis, Lactobacillus coleohominis, Lactobacillus crispatus, Lactobacillus crustorum, Lactobacillus curvatus, Lactobacillus diolivorans, Lactobacillus farraginis, Lactobacillus fermentum, Lactobacillus fuchuensis, Lactobacillus harbinensis, Lactobacillus helveticus, Lactobacillus hilgardii, Lactobacillus intestinalis, Lactobacillus jensenii, Lactobacillus kefiranofaciens, Lactobacillus kefiri, Lactobacillus lindneri, Lactobacillus mali, Lactobacillus manihotivorans, Lactobacillus mucosae, Lactobacillus oeni, Lactobacillus oligofermentans, Lactobacillus panis, Lactobacillus pantheris, Lactobacillus parabrevis, Lactobacillus paracollinoides, Lactobacillus parakefiri, Lactobacillus paraplantarum, Lactobacillus pentosus, Lactobacillus pontis, Lactobacillus reuteri, Lactobacillus rossiae, Lactobacillus salivarius, Lactobacillus siliginis, Lactobacillus sucicola, Lactobacillus vaccinostercus, Lactobacillus vaginalis, Lactobacillus vini, Lactococcus garvieae , or Lactococcus lactis ; the Faecalibacterium sp., is Faecalibacterium prausnitzii ; and the Akkermansia sp. is Akkermansia muciniphila.
7. The pharmaceutical composition of claim 1 , wherein the purified bacterial population further comprises Bifidobacterium sp.
8. The pharmaceutical composition of claim 7 , wherein the Bifidobacterium sp. is Bifidobacterium bifidum, Bifidobacterium pseudolongum, Bifidobacterium saeculare , or Bifidobacterium subtile.
9. The pharmaceutical composition of claim 1 , wherein the purified bacterial population comprises less than about 20 species of bacteria.
10. The pharmaceutical composition of claim 1 , further comprising Cystobacter sp.
11. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is formulated as an oral dosage form.
12. The pharmaceutical composition of claim 11 , wherein the oral dosage form comprises a pharmaceutically acceptable excipient.
13. The pharmaceutical composition of claim 12 , wherein the pharmaceutically acceptable excipient comprises saline solution, glycerin, or a combination thereof.
14. The pharmaceutical composition of claim 1 , wherein the Lactobacillus sp. is Lactobacillus johnsonii , wherein the Faecalibacterium sp. is Faecalibacterium prausnitzii , and wherein the Akkermansia sp. is Akkermansia muciniphila.
15. The pharmaceutical composition of claim 1 , wherein Lactobacillus sp. is Lactobacillus crispatus , wherein the Faecalibacterium sp. is Faecalibacterium prausnitzii , and wherein the Akkermansia sp. is Akkermansia muciniphila.
16. The pharmaceutical composition of claim 1 , wherein the purified bacterial population is live bacteria.
17. The pharmaceutical composition of claim 1 , wherein each member of the purified bacterial population is present in an amount of 10 3 to 10 15 colony forming units (cfu)/g.
18. The pharmaceutical composition of claim 1 , wherein each member of the purified bacterial population is present in an amount of about 10 7 or 10 8 colony forming units (cfu).
19. The pharmaceutical composition of claim 1 , wherein each member of the purified bacterial population is present in an amount of 10 3 to 10′ 5 colony forming units (cfu).